Does lowering serum uric acid in patients with gout improve cardiovascular outcomes?

Does Reducing Uric Acid in Gout Improve Cardiovascular Outcomes?

Yes, achieving target serum uric acid levels below 6 mg/dL in patients with gout is associated with reduced cardiovascular events and mortality, particularly in those at high cardiovascular risk. The most recent high-quality evidence demonstrates that treat-to-target urate-lowering therapy reduces major adverse cardiovascular events by approximately 9% over 5 years, with even greater benefit (23% reduction) when achieving levels below 5 mg/dL 1.

The Evidence for Cardiovascular Benefit

The 2026 JAMA Internal Medicine study—the highest quality and most recent evidence available—analyzed 109,504 patients with gout newly prescribed urate-lowering therapy (ULT) 1. Patients who achieved serum uric acid <6 mg/dL within 12 months had:

• 1.0% higher 5-year survival
• 9% lower risk of major adverse cardiovascular events (weighted HR 0.91,95% CI 0.89-0.92)
• Greater benefit in those at high and very high cardiovascular risk
• Even larger risk reduction (23%) when achieving <5 mg/dL target

This finding is supported by meta-analytic data showing ULT reduces all-cause mortality by 22% in gout patients (HR 0.783,95% CI 0.702-0.874) 2. The cardiovascular benefit appears specific to achieving target uric acid levels through a treat-to-target approach, not merely prescribing ULT 3.

Why Current Guidelines Don't Explicitly Address This

Important caveat: The major gout management guidelines (EULAR 2016, ACR 2020, ACP 2017) do not explicitly recommend ULT for cardiovascular risk reduction 4, 5. These guidelines focus on gout-specific outcomes (flares, tophi, joint damage) because they were published before the definitive cardiovascular outcomes data emerged. However, they do recognize cardiovascular comorbidities as important considerations:

• EULAR recommends screening all gout patients for cardiovascular risk factors and states that ULT initiation is recommended in patients with comorbidities including "ischaemic heart disease, heart failure" 4
• The 3e Initiative recommends measuring renal function and assessing cardiovascular risk factors in all gout patients 6
• KDIGO 2024 conditionally recommends initiating ULT after the first gout episode, particularly in patients with CKD stages 3-5 7

Clinical Algorithm for ULT in Gout with Cardiovascular Considerations

1. Identify patients who should receive ULT:

• Any patient with recurrent flares (≥2 per year), tophi, urate arthropathy, or renal stones (strong indication) 4
• First presentation with cardiovascular disease, heart failure, or high cardiovascular risk (strong consideration) 4, 1
• Young age (<40 years) or very high baseline uric acid (>8.0 mg/dL) 4

2. Set the target serum uric acid:

• Standard target: <6 mg/dL (360 μmol/L) for all patients 4, 6
• Lower target: <5 mg/dL (300 μmol/L) for severe gout (tophi, chronic arthropathy, frequent attacks) AND for patients at high cardiovascular risk based on the 2026 data 4, 1
• Never target <3 mg/dL long-term 4

3. Choose first-line ULT:

• Allopurinol is first-line for normal renal function 4, 6, 5

  • Start 100 mg daily, increase by 100 mg every 2-4 weeks to reach target 4
  • Can dose up to 800 mg daily if needed to achieve target 3
  • In CKD, start 50-100 mg daily and uptitrate with monitoring 7
  • Consider HLA-B*5801 testing in Southeast Asian (Han Chinese, Korean, Thai) and African American patients before starting 5

• Febuxostat has cardiovascular safety concerns: the CARES trial showed increased cardiovascular death compared to allopurinol 5. Switch patients with established CVD from febuxostat to alternative ULT 5. However, network meta-analysis suggests febuxostat may have the highest probability of reducing MACE 8—this contradiction reflects ongoing uncertainty.

4. Provide flare prophylaxis:

• Colchicine 0.5-1 mg daily for first 6 months of ULT 4
• Reduce dose in renal impairment; avoid with strong CYP3A4 inhibitors 4
• If colchicine contraindicated: low-dose NSAID or low-dose corticosteroid 4

5. Monitor and titrate to target:

• Measure serum uric acid regularly and adjust ULT dose until target achieved 4
• Maintain target lifelong 4
• Monitor gout flare frequency—should decrease after ~12 months 9

Key Nuances and Pitfalls

The treat-to-target vs. treat-to-avoid-symptoms debate: The ACP 2017 guideline questions whether monitoring uric acid and treating to target is superior to simply treating symptoms 10. However, the 2026 JAMA study provides strong evidence that achieving specific uric acid targets (<6 mg/dL, ideally <5 mg/dL) is associated with cardiovascular benefit 1. This supports the treat-to-target approach, particularly in patients with cardiovascular disease.

Allopurinol underdosing is common: Real-world data shows mean prescribed allopurinol doses of only 253 mg/day in cardiovascular patients, with only 33% of patients with tophi achieving target levels 11. Don't stop at 300 mg—titrate up to 800 mg if needed to reach target 3.

The cardiovascular benefit requires achieving target: Simply prescribing ULT without achieving serum uric acid <6 mg/dL does not provide cardiovascular benefit 1. This is why monitoring and dose titration are essential.

Asymptomatic hyperuricemia without gout: Do NOT treat asymptomatic hyperuricemia solely for cardiovascular risk reduction 6, 12. The evidence for cardiovascular benefit is specific to patients with established gout.

Colchicine has independent cardiovascular benefits: Beyond its role in gout, colchicine reduces acute cardiovascular events in patients with coronary artery disease 3. This provides additional rationale for its use in gout patients with cardiovascular disease.

Bottom Line for Clinical Practice

For patients with gout and cardiovascular disease or high cardiovascular risk, initiate allopurinol and titrate aggressively to achieve serum uric acid <6 mg/dL, ideally <5 mg/dL 1. This approach reduces both gout flares and cardiovascular events. The cardiovascular benefit emerges after approximately 12 months of maintaining target uric acid levels 1. Provide colchicine prophylaxis for 6 months when starting ULT 4. Monitor serum uric acid regularly and don't accept subtherapeutic dosing—most patients need more than 300 mg allopurinol daily to reach target 11.